You are here: Industry Insights > antibody

News List

Samsung Biologics, STCube Ink Cancer Drug Deal contractpharma
March 09, 2020
Enter into development and manufacturing agreement for novel target anticancer drug.
Absolute Antibody Launches FleXpress contractpharma
March 06, 2020
High-throughput recombinant antibody production service enables rapid production of large numbers of recombinant antibodies at 80 ml scale.
Antibody Production Successfully Induced in the First Batch of Vaccines fmprc
February 25, 2020
Song Zhiheng, deputy head of the Science and Technology Department of Zhejiang Province, said that the first batch of vaccines has successfully induced antibody production and entered the stage of animal test.
Roche HER2-ADC Enmetrastuzumab has been approved for marketing in China En-CPhI.CN
January 19, 2020
Detailed story will be updated soon, please stay tuned with us.
Important Progresses of New Drugs Marketed in China in 2019 En-CPhI.CN
January 07, 2020
Imported Drugs:1、Novartis CTL019 Applied for Clinical Trial in China to Officially Enter the Chinese Market Novartis f
FDA Approves New Drug, PADCEV to Treat Locally Advanced or Metastatic Urothelial Cancer Lin Zhang
January 03, 2020
A new drug, PADCEV (enfortumab vedotin-ejfv) to treat patients with locally advanced or metastatic urothelial cancer, was approved under the FDA’s Accelerated Approval Program based on tumor response rate.
Genmab, CureVac Enter Partnership to Develop mRNA-based Antibody Therapeutics americanpharmaceuticalreview
December 23, 2019
Genmab and CureVac have entered into a research collaboration and license agreement. This strategic partnership will focus on the research and development of ...
WuXi Biologics Congratulates Tychan on Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers En-CPhI.CN
November 19, 2019
WuXi Biologics congratulates its partner Tychan on successful completion of the Phase 1A/1B safety and efficacy trials in Singapore for TY014, a first-in-class monoclonal antibody candidate treatment for Yellow Fever (YF).
I-Mab novel antibody gets IND approval in China biospectrumasia
October 08, 2019
TJD5 is currently being investigated in a Phase 1 clinical trial in the U.S. to assess the tolerability and preliminary efficacy both as a single agent and in combination with TECENTRIQ® (atezolizumab), a PD-L1 antibody marketed by Roche in the U.S., and
I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5 En-CPhI.CN
October 08, 2019
I-Mab Biopharma , a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page